Subcategory
Pancreatic cancer, Non-small cell lung cancer (NSCLC), Small cell lung carcinoma
Trial Type
other systemic therapies
Description for experts
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Description for laymen
The objective of this study is to evaluate the safety, tolerability and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
JSON Data
{
"short_title": "BMS CA052-002",
"data_mode": "900",
"data_mode_number": "000002244",
"official_title": "A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "not_applicable",
"ctgov_number": "NCT04895709",
"eudract_number": "2021-001188-26",
"general_contact_email": "ectu@ukdd.de",
"general_contact_phone": "+49 351-4587566",
"hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke",
"description_laie_de": "Ziel dieser Studie ist es, die Sicherheit, Vertr\u00e4glichkeit und empfohlene(n) Dosis(en) von BMS-986340 als Monotherapie und in Kombination mit Nivolumab bei Teilnehmern mit fortgeschrittenen soliden Tumoren zu untersuchen. Bei dieser Studie handelt es sich um eine First-in-Human-Studie (FIH) zu BMS-986340 bei Teilnehmern mit fortgeschrittenen soliden Tumoren.",
"description_laie_en": "The objective of this study is to evaluate the safety, tolerability and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.",
"description_expert_de": "Ziel dieser Studie ist es, die Sicherheit, Vertr\u00e4glichkeit und empfohlene(n) Dosis(en) von BMS-986340 als Monotherapie und in Kombination mit Nivolumab bei Teilnehmern mit fortgeschrittenen soliden Tumoren zu untersuchen. Bei dieser Studie handelt es sich um eine First-in-Human-Studie (FIH) zu BMS-986340 bei Teilnehmern mit fortgeschrittenen soliden Tumoren.",
"description_expert_en": "The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "I_II",
"main_cat_id": 10,
"sub_cat_id": 51
}
